



European Bone Marrow Working Group - Policy plan

KvK number: 94911339

RSIN number: 866933918

1. The purpose of the institution and the activities to achieve that goal

The primary purpose of the European Bone Marrow Working Group (EBMWG) is to advance the field of bone marrow (haemato)pathology, both within and beyond Europe. In doing so, the EBMWG contributes to the improvement of current and future diagnostics and, indirectly, to the treatment of patients with bone marrow diseases.

To achieve this, the EBMWG organizes scientific meetings, workshops, tutorials, and seminars aimed at increasing knowledge of bone marrow pathology among pathologists (in training) and other scientists worldwide.

In addition, the EBMWG promotes scientific collaboration among its members, encourages the integration of relevant data from allied disciplines, facilitates the exchange of ideas and dissemination of knowledge globally, and works in close cooperation with related societies. These include, in particular, the European Association for Haematopathology (EA4HP), and to some extent the European Society of Pathology (ESP) and the Society for Hematopathology (SH). The group also seeks to stimulate interest in research and support the development of improved technologies and methodologies.

2. Income generation

The main sources of income are memberships fees (€100 per year, starting from Jan 2026) and surpluses from the biannual Course and Workshop organized by the EBMWG. Additional income may be generated through voluntary donations.

3. Expenditure

Funds are used to support the organization of scientific and educational events, and to cover professional administrative and financial management services.

4. Asset Management

An annual budget is prepared and approved by the General Meeting, outlining expected revenues and expenditures. At the end of each financial year, a financial report including a balance sheet is prepared, providing a clear overview of the EBMWG's assets and liabilities. The annual accounts are approved by the General Meeting within five months after the close of the financial year.

In accordance with Article 14.2 of the Deed of Incorporation, the General Meeting decides on the allocation of any positive balance. This surplus must be transferred to a public benefit organization—or its foreign equivalent—with at least 90% of its activities aimed at the public benefit and with objectives comparable to those of the EBMWG.